Dark Forest Capital Management LP Makes New Investment in United Therapeutics Co. (NASDAQ:UTHR)

Dark Forest Capital Management LP purchased a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,257 shares of the biotechnology company’s stock, valued at approximately $400,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. ClariVest Asset Management LLC increased its stake in United Therapeutics by 120.0% during the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 42 shares during the period. V Square Quantitative Management LLC bought a new stake in United Therapeutics during the second quarter worth approximately $30,000. Innealta Capital LLC bought a new position in United Therapeutics during the 2nd quarter valued at $33,000. Rise Advisors LLC acquired a new position in shares of United Therapeutics during the 1st quarter valued at $32,000. Finally, Benjamin F. Edwards & Company Inc. raised its stake in shares of United Therapeutics by 63.6% in the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock worth $69,000 after buying an additional 117 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on UTHR shares. Oppenheimer raised their target price on United Therapeutics from $400.00 to $575.00 and gave the company an “outperform” rating in a research note on Wednesday, August 28th. Wells Fargo & Company lifted their price objective on shares of United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 20th. TD Cowen increased their target price on shares of United Therapeutics from $270.00 to $350.00 and gave the company a “buy” rating in a research note on Thursday, July 11th. Bank of America decreased their price target on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a research report on Thursday, August 1st. Finally, Morgan Stanley downgraded United Therapeutics from an “overweight” rating to an “equal weight” rating and increased their price objective for the company from $310.00 to $321.00 in a research report on Thursday, July 11th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $357.17.

United Therapeutics Trading Up 0.2 %

NASDAQ:UTHR opened at $358.53 on Friday. The stock’s 50-day moving average is $342.08 and its two-hundred day moving average is $295.69. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.35 and a quick ratio of 4.18. The stock has a market cap of $15.95 billion, a PE ratio of 16.95, a price-to-earnings-growth ratio of 1.29 and a beta of 0.57. United Therapeutics Co. has a fifty-two week low of $208.62 and a fifty-two week high of $366.08.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The company had revenue of $714.90 million for the quarter, compared to analyst estimates of $691.87 million. During the same period last year, the business earned $5.24 EPS. The company’s quarterly revenue was up 19.8% on a year-over-year basis. As a group, equities research analysts forecast that United Therapeutics Co. will post 24.84 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction that occurred on Wednesday, July 3rd. The stock was sold at an average price of $312.48, for a total value of $1,124,928.00. Following the completion of the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $40,622.40. The sale was disclosed in a document filed with the SEC, which is available at this link. In related news, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction on Wednesday, July 3rd. The shares were sold at an average price of $312.48, for a total value of $1,124,928.00. Following the completion of the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $40,622.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 269 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $348.41, for a total transaction of $93,722.29. Following the transaction, the chief executive officer now directly owns 130 shares in the company, valued at $45,293.30. The disclosure for this sale can be found here. Insiders have sold a total of 111,252 shares of company stock valued at $36,939,427 in the last three months. Insiders own 12.50% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.